Donald Trump wins key states, edges closer to White House

Washington, Feb 18: The upcoming visit of President Donald Trump to India later this month has the potential to usher in a new era of bilateral ties between the two countries, a top American business advocacy group has said.

President Trump will pay a state visit to India on February 24 and 25 at the invitation of Prime Minister Narendra Modi. He would be accompanied by First Lady Melania Trump.

This would be the president's first bilateral visit in the third decade of the 21st century and also the first after his acquittal by the Senate in the impeachment trial.

"I believe President Trump's upcoming visit to India has the potential to usher in a new era of our bilateral ties," Mukesh Aghi, President of the US India Strategic and Partnership Forum (USISPF) said in a statement on Monday.

On the sidelines of the visit, the USISPF, in collaboration with the Federation of Indian Chambers of Commerce and Industry (FICCI) and the ORF, has announced to organise a program entitled "US-India Forum: Partners for Growth".

The full-day discussion will focus on the key pillars defining India and the US' strategic, economic, and cultural partnership over the next decade.

"We have an opportunity before us to make real progress on multiple aspects of the relationship— whether it is upholding peace and security in the Indo-Pacific region; building upon an already strong energy partnership; developing co-production and co-development opportunities in the defense space; or strengthening bilateral trade," Aghi said.

"We look forward to an extremely successful visit and some concrete outcomes from the visit," he said.

The day-long programme on February 25 in New Delhi, will bring together over 500 senior business executives, members of the US-India think tank community and leading figures of the Indian diaspora to set the agenda for this strategic partnership.

Discussions during the day will touch upon areas, including the Indo-Pacific Strategy and Maritime Security; the US-India Defence Partnership, the US-India Energy Partnership, Elevating US-India Trade and Investment and Role of the Indian Diaspora in US-India Relations.

Moscow, Jul 13: Russia has become the first nation to complete clinical trials of a COVID-19 vaccine on humans. Chief researcher Elena Smolyarchuk, who heads the Center for Clinical Research on Medications at Sechenov University, told Russian news agency TASS on Sunday that the human trials for the vaccine have been completed at the university and the volunteers will be discharged soon.

"The research has been completed and it proved that the vaccine is safe. The volunteers will be discharged on July 15 and July 20," Smolyarchuk was quoted as saying in the report.

Though the results have been favourable with respect to the medication’s effectiveness, no further information was provided on when this vaccine would enter commercial production stage.

Russia had allowed clinical trials of two forms of a potential COVID-19 vaccine developed by the Gamaleya National Research Center for Epidemiology and Microbiology on June 18.

The first vaccine, in the form of a solution for intramuscular administration, was carried out at the Burdenko Military Hospital.

Another vaccine, in the form of a powder for the preparation of a solution for intramuscular administration, was carried out at Sechenov First Moscow State Medical University.

The first stage of research on the vaccine at Sechenov University involved a group of 18 volunteers and the second group involved 20 volunteers.

After vaccination, all volunteers were expected to remain in isolation in a hospital for 28 days.

Earlier, results of the COVID-19 vaccine tests performed on a group of volunteers in Russia showed that they were developing immunity to the coronavirus.

"The data obtained by the Gamalei National Research Center for Epidemiology and Microbiology, proves that volunteers of the first and second groups are forming an immune response after injections of the vaccine against the coronavirus," according to an earlier statement from the Russian Defense Ministry.

Russia has reported 719,449 cases and 11,188 deaths to date.

There are at least 21 vaccines currently under key trials, according to the World Health Organisation (WHO).

The overall number of global COVID-19 cases crossed 12.9 million, while the deaths have increased to more than 5,69,000, according to Johns Hopkins University in the US.

As of Monday morning, the total number of cases stood at 1,29,10,357, while the fatalities rose to 5,69,128.

The US accounted for the world's highest number of infections at over 33 lakh. Brazil came in the second place with over 18 lakh infections. India is third worst affected with over 8.7 lakh people reported to have COVID-19.

New Delhi, Mar 24: Reports of a person in China dying due to a virus called hantavirus have spread panic at a time when the world is battling the pandemic of novel coronavirus, which began in China.

The novel coronavirus has killed over 16,000 people around the world and the outbreak is yet to be brought under control.

This morning, hantavirus became one of the top trends on Twitter after the Chinese state media tweeted about one person in the country dying due the virus. However, it turns out, hantavirus is not a new virus and has been infecting humans for decades.

Global Times, a state-run English-language newspaper, wrote on Twitter on Tuesday, "A person from Yunnan Province died while on his way back to Shandong Province for work on a chartered bus on Monday. He was tested positive for hantavirus. Other 32 people on bus were tested."

Global Times's hantavirus report on Twitter has been shared over 6,000 times.

On Tuesday, hantavirus was one of the top trends on Twitter.

WHAT IS HANTAVIRUS?

Some people are calling it a new virus but so is not the case. United States's National Center for Biotechnology Information (NCBI) in a journal writes that currently, the hantavirus genus includes more than 21 species.

"Hantaviruses in the Americas are known as 'New World' hantaviruses and may cause hantavirus pulmonary syndrome [HPS]," CDC says. "Other hantaviruses, known as 'Old World' hantaviruses, are found mostly in Europe and Asia and may cause hemorrhagic fever with renal syndrome [HFRS]."

Any man, woman, or child who is around mice or rats that carry harmful hantaviruses can get HPS.

People get HPS when they breath in hantaviruses. This can happen when rodent urine and droppings that contain a hantavirus are stirred up into the air. People can also become infected when they touch mouse or rat urine, droppings, or nesting materials that contain the virus and then touch their eyes, nose, or mouth. They can also get HPS from a mouse or rat bite.

In the US, 10 confirmed cases of hantavirus infection in people who visited Yosemite National Park in California, US, in November 2012, were reported. Similarly, in 2017, CDC assisted health officials in investigating an outbreak of Seoul virus infection that infected 17 people in seven states.

WHAT ARE THE SYMPTOMS OF HANTAVIRUS?

If people get HPS, they will feel sick one to five weeks after they were around mice or rats that carried a hantavirus.

At first people with HPS will have:

Fever
Severe muscle aches
Fatigue

After a few days, they will have a hard time breathing. Sometimes people will have headaches, dizziness, chills, nausea, vomiting, diarrhoea, and stomach pain.

Usually, people do not have a runny nose, sore throat, or a rash.